C3G is minimally responsive to traditional immune suppression and randomized controlled trials to support therapy are lacking (Nester CM, et al. Curr Opin Nephrol Hypertens. 2013;22(2):231-7).
Anticellular immune suppression and plasma therapy have limited efficacy in C3G (Nester CM, et al. Curr Opin Nephrol Hypertens. 2013;22(2):231-7).
The use of terminal complement blockade and a few other reports suggest that the anticomplement drug eculizumab may offer a therapeutic advantage in C3G (Nester CM, et al. Curr Opin Nephrol Hypertens. 2013;22(2):231-7).
It was seen in GLOSEN study that immunosuppressive treatments, particularly corticosteroids plus mycophenolate mofetil, can be beneficial in C3 glomerulonephritis. (Rabasco C, et al. Kidney Int. 2015;88(5):1153-60).
To comment on this article, create a free account.
Sign Up to instantly get access to 10000+ Articles & 1000+ Cases
eMediNexus provides latest updates on medical news, medical case studies from India. In-depth medical case studies and research designed for doctors and healthcare professionals.